Rheumatoid Arthritis

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

This new research presented at ACR Convergence 2023 led to several notable findings for patients with rheumatoid arthritis.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

JB Boone, MD, explains the progress being made towards more personalized medicine in patients with rheumatoid arthritis, as well as the current challenges.

JB Boone, MD, explains PrismRA, a predictive tool designed to determine whether a patient will likely have an inadequate response to a TNF inhibitor.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Patients with IBD-RA and depression were younger, more likely to be female, and were more frequently White compared with controls.

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Patients receiving TNF, JAK, and CTLA4-Ig all demonstrated higher discontinuation rates due to ineffectiveness when compared to aIL-6R treatment.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Although patients in both the intervention and control cohorts gained weight, patients treated with glucocorticoids gained an average of 1.1 kg more than controls.

The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).

At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.

The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.

No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.

Improvements in CDAI by >5 points were associated with improvements in the 5 PROMIS domains and increased satisfaction with rheumatoid arthritis treatment.

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

In this episode of Relatable Rheumatology, experts discuss a critically important topic for patients with rheumatoid arthritis: bloodwork and laboratory tests.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.